SODIUM BICARBONATE IN PLASTIC CONTAINER
Clinical safety rating
safeCan decrease the levels of many drugs by increasing urinary pH Can cause metabolic alkalosis and fluid overload.
Sodium bicarbonate dissociates to provide bicarbonate ion, which neutralizes hydrogen ions and increases blood pH. It also acts as a buffer in acid-base disorders.
| Metabolism | Sodium bicarbonate is not metabolized; it dissociates into sodium and bicarbonate ions in body fluids. Bicarbonate is primarily eliminated via the kidneys (renal excretion) and lungs (conversion to CO2). |
| Excretion | Renal: >99% as bicarbonate and carbon dioxide. Minimal biliary/fecal elimination. |
| Half-life | 5–7 minutes (bicarbonate in plasma); short due to rapid equilibration with CO2 and renal excretion. Continuous infusion required for sustained effect. |
| Protein binding | <1% (essentially negligible; not significantly protein bound). |
| Volume of Distribution | 0.4–0.5 L/kg (distributes into extracellular fluid; minimal intracellular penetration). |
| Bioavailability | Intravenous: 100%; Oral: ~100% (completely absorbed; but effect on systemic pH is limited due to rapid renal elimination and buffering). |
| Onset of Action | Intravenous: 2–5 minutes (correction of acidosis). Oral: 1–2 hours (gastric pH neutralization). |
| Duration of Action | Intravenous: 30 minutes to 1 hour (pH effect); oral: 1–3 hours (antacid effect). Duration is short; repeated doses often needed. |
| Molecular Weight | 84.007 |
IV: 1 mEq/kg/dose initial, then 0.5 mEq/kg/dose every 10 minutes as needed; max 8 mEq/kg/day. Also given as IV infusion: 50-150 mEq in 1 L D5W at 1-1.5 L/hour for metabolic acidosis. Oral: 325-2000 mg 1-4 times daily.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment for GFR; however, sodium bicarbonate can cause fluid overload and metabolic alkalosis in renal impairment. Use with caution in patients with GFR <30 mL/min; monitor serum sodium and bicarbonate levels closely. |
| Liver impairment | No specific dose adjustment based on Child-Pugh score. Use with caution in severe hepatic impairment due to risk of fluid overload and alkalosis. |
| Pediatric use | IV: 1 mEq/kg/dose slow IV push (not to exceed 10 mEq/min) for acute acidosis; may repeat in 10-15 minutes. Oral: 1-5 mEq/kg/day in divided doses; typical starting dose 1-2 mEq/kg/day. |
| Geriatric use | Use lowest effective dose; monitor for fluid overload, electrolyte imbalances, and metabolic alkalosis. Initiate at 25-50% of adult dose and titrate slowly due to decreased renal function and comorbidities. |
| 1st trimester | Sodium bicarbonate is generally considered safe in the first trimester when used at recommended doses for conditions such as metabolic acidosis or urinary alkalinization. However, use should be cautious due to potential electrolyte imbalances. There are no well-controlled studies in pregnant women, but animal reproduction studies have not shown fetal harm. |
| 2nd trimester | Same as first trimester. Safety data are limited, but no teratogenic effects have been reported. Use only if clearly needed. |
| 3rd trimester | Use with caution in the third trimester, especially near term, as high doses may cause maternal metabolic alkalosis and affect fetal acid-base balance. May also lead to fluid overload or electrolyte disturbances in the mother. |
Clinical note
Can decrease the levels of many drugs by increasing urinary pH Can cause metabolic alkalosis and fluid overload.
| FDA category | Animal |
| Placental transfer | Sodium bicarbonate crosses the placenta. Studies indicate that maternal administration can increase fetal bicarbonate levels, affecting fetal acid-base status. The degree of transfer depends on maternal dose and acid-base balance. |
| Breastfeeding | Sodium bicarbonate is excreted into breast milk, but the amount is unlikely to produce clinically significant effects in the infant. However, caution is advised with high maternal doses as the infant may be exposed to increased sodium load and potential alkalosis. Monitor infant for signs of electrolyte imbalance. |
| Lactation Rating | L2 (Probably Compatible) - Limited data suggest low risk. |
| Teratogenic Risk | Sodium bicarbonate is not known to be teratogenic in humans. In animal studies, no teratogenic effects were observed at doses equivalent to human therapeutic doses. However, during pregnancy, especially in the first trimester, use only if clearly needed and potential benefit justifies risk to the fetus. Administration during labor may lead to metabolic alkalosis and hypernatremia in the neonate. |
| Fetal Monitoring | Monitor maternal serum electrolytes (sodium, bicarbonate, potassium), acid-base status (pH, pCO2), and renal function. Fetal monitoring may include assessment of fetal heart rate and acid-base status if maternal administration occurs during labor, as rapid correction of maternal acidosis can cause shifts in fetal pH. |
| Fertility Effects | No known adverse effects on fertility in animal or human studies. Sodium bicarbonate does not impair reproductive function at therapeutic doses. |
■ FDA Black Box Warning
No FDA boxed warning exists for sodium bicarbonate.
| Common Effects | hyperkalemia |
| Serious Effects |
Metabolic alkalosisRespiratory alkalosisHypocalcemia (may precipitate tetany)Severe renal impairment (creatinine clearance < 30 mL/min unless dialysis)HypernatremiaUncontrolled hypertensionEdema or congestive heart failure (risk of fluid overload)
| Precautions | Risk of hypernatremia, hyperosmolality, and fluid overload, especially in patients with renal impairment or heart failure., Paradoxical intracellular acidosis may occur due to rapid CO2 generation., Extravasation can cause tissue necrosis (administer via central line if concentrated solutions)., Avoid excessive doses; monitor serum electrolytes, pH, and calcium levels. |
| Food/Dietary | Avoid high-sodium foods during therapy to prevent fluid overload. No specific food interactions are known. |
| Clinical Pearls | Sodium bicarbonate in plastic container is used for metabolic acidosis treatment. Avoid rapid administration in neonates due to risk of hypernatremia and intraventricular hemorrhage. Monitor serum sodium, bicarbonate, and pH during infusion. Do not administer with calcium-containing solutions to prevent precipitation. Plastic containers may leach DEHP; use with caution in pediatric patients. |
| Patient Advice | This medication is given intravenously to correct acidosis. · You may experience swelling at the injection site; report any pain or redness. · Adverse effects include headache, nausea, and muscle cramps. · Inform your healthcare provider if you have heart failure, kidney disease, or are on a sodium-restricted diet. · Do not mix this medication with other drugs without consulting a pharmacist. |
Loading safety data…